US House committee opens investigations into five drugmakers over clinical trials in China

The U.S. House Select Committee on China has opened investigations into five pharmaceutical companies regarding their clinical trials in China, questioning whether the drugmakers may have aided the country’s military biotechnology research.Representatives from AbbVie, Bristol Myers Squibb, Eli Lilly & Co., Merck and Pfizer have until July 17 to answer letters sent to each by committee